Victor Babes University of Medicine and Pharmacy Timisoara
Timisoara, Romania

The Victor Babeș University of Medicine and Pharmacy, Timișoara is located in Timişoara, Romania. Wikipedia.

Time filter
Source Type

Board Of Supervisors Of Lousiana State University, Victor Babes University of Medicine and Pharmacy Timisoara | Date: 2017-06-21

Methods and compositions are disclosed for delivering lutein or other antioxidant to target tissues such as the eye, in bioactive form, while protecting the antioxidant from degradation. The antioxidant is encapsulated in nanoparticles comprising a protein such as zein or a polymer such as poly(lactic-co-glycolic acid) (PLGA). Preferably a surfactant is associated with the nanoparticles as well, further helping to protect the antioxidant. After the nanoparticles are administered to the target tissue, bioactive antioxidant is released to the tissue over time. Optionally, the nanoparticles are admixed with a thermosensitive, bioadhesive gel to promote slow release of antioxidant. The methods and compositions are useful for treating or preventing conditions such as age-related macular degeneration or cataracts.

Agency: European Commission | Branch: FP7 | Program: CP-CSA | Phase: Fission-2013-3.1.1 | Award Amount: 10.26M | Year: 2013

Within the OPERRA project, it is proposed that the MELODI Association, as a well-advanced network, takes the lead in establishing the necessary structures able to manage the long-term European research programmes in radiation protection, also taking advantage of the valuable experience gathered through the DoReMi network of excellence. Whilst in fields adjacent to low-dose risk research (radioecology, nuclear emergency management) scientific issues would continue to be hosted by the sister associations, Alliance and NERIS, these associations are encouraged to join MELODI to establish an umbrella structure as equal partners. OPERRA will exploit the synergies of EURATOM and other EC programmes considering the most relevant joint program areas and mechanisms for funding joint activities. The project will also strengthen the links with national funding programs as well as the European education and training structures. Also, it will take steps towards a greater involvement of those new Member States who could benefit from increased participation in the radiation research programmes. Finally, OPERRA will take steps to further integrate the joint use of infrastructures in European countries, and to develop and facilitate an easier access to research infrastructures. The final objective of this project is to build up an umbrella coordination structure that has the capacity in a legal and logistical sense to administer future calls for research in radiation protection as a whole (including low-dose risk, radioecology, nuclear emergency management, and also research activities related to the medical uses of ionizing radiation) on behalf of the European Commission. OPERRA will prepare the organisation for a first competitive call by the end of 2013 for projects in low-dose risk research and a second competitive call in 2014 for broader projects in radiation protection research, subject to the approval of EC services, with the support of Go-between administrator operator and an external advisory entity.

Serban C.,Victor Babes University of Medicine and Pharmacy Timisoara | Dragan S.,Victor Babes University of Medicine and Pharmacy Timisoara
Current Pharmaceutical Design | Year: 2014

Atherosclerotic cardiovascular disease is the leading cause of death in many developed countries. It is characterized by complex endocrine, paracrine and juxtacrine interactions between immune and vascular cells, as well as several tissues and organs. Oxidative stress and inflammation have an important role in the promotion of atherosclerotic cardiovascular disease. Considering the complicated mechanisms and signals involved in atherosclerosis, research is focused on blood-based biomarkers, gene-based markers, metabolomics and other potentially interesting approaches for biomarker discovery. These biomarkers can be introduced as routine diagnostic tests if they prove to be cost-effective and to predict future cardiovascular events. Given the overlap of circulating inflammatory and oxidative stress biomarkers in atherosclerosis and rheumatic diseases, we aim to overview their potential to screen cardiovascular risk and also to predict the evolution of associated rheumatic diseases. © 2014 Bentham Science Publishers.

Antoniu S.A.,Victor Babes University of Medicine and Pharmacy Timisoara
Current Opinion in Investigational Drugs | Year: 2010

In asthma, airway inflammation is driven by Th2-related cytokines, such as IL-4, IL-5 and IL-13. IL-4 and IL-13, in particular, have a major role in the development of airway hyperresponsiveness, allergen-specific IgE synthesis and airway remodeling because of their synergistic effects induced by binding to the IL-4Rα subunit. Pitrakinra (AER-001, BAY-16-9996), being developed by Aerovance, under license from Bayer, for the potential treatment of asthma and eczema, is an IL-4 mutein, which binds to the IL-4Rα subunit and prevents the inflammation induced by IL-4 and IL-13. Pitrakinra demonstrated a potent inhibitory activity on IL-4/IL-13-mediated proliferative effects in vitro and reduced allergen-induced inflammation in animal models of asthma and skin inflammation. In phase I and II clinical trials in patients with asthma, subcutaneous and inhaled (as dry powder or nebulized) formulations of pitrakinra reduced airway inflammation, with superior effects observed with inhaled formulations. At the time of publication, a phase II clinical trial with the dry powder formulation of pitrakinra was ongoing in patients with asthma. Subcutaneous pitrakinra demonstrated preliminary efficacy results in patients with atopic eczema in a phase II clinical trial and a PEGylated variant of subcutaneous pitrakinra is being investigated for this indication. Further studies are warranted to allow a better therapeutic positioning and a more detailed characterization of the efficacy and safety of pitrakinra in asthma and atopic eczema. © Thomson Reuters (Scientific) Ltd.

Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2011.4.2-1 | Award Amount: 7.78M | Year: 2011

Dobutamine and adrenaline are widely used as second line therapy for systemic hypotension in infants. Dopamine is currently the most widely used first line drug. In neonates, sustained hypotension may, and impaired organ perfusion will, cause brain injury and poor neurodevelopmental outcomes. All three catecholamines are currently used off-label and have different modes of action which may result in potentially harmful haemodynamic effects. No reliable safety or efficacy data exists for the use of these drugs in neonates or newborns. Furthermore, no uniform criteria exist to define hypotension and there is little evidence to support current intervention strategies, which vary widely. Recently, superior vena cava (SVC) flow has been proposed as a more reliable indicator of circulatory failure than low blood pressure and preliminary results suggest Dobutamine is the optimum therapeutic in such cases. NEO-CIRC proposes 1) a randomised placebo controlled trial to provide safety and efficacy data for Dobutamine as a first line inotrope for all gestational ages 2) to perform pre-clinical; pharmacokinetic; pharmacodynamic; metabolomic and pharmacogenomic studies 3) to develop improved biomarkers of hypotension 4) to develop and adapt a formulation of Dobutamine suitable for newborns with the aim to apply for a Paediatric Use Marketing Authorisation. The NEO-CIRC consortium includes international experts in neonatal medicine, pharmacology, pharmacogenomics, drug formulation and pre-clinical neonatal models and an experienced group of experienced multicentre clinical trials NICUs. Outcomes anticipated include improved biomarkers of organ perfusion; a new consensus definition of neonatal circulatory failure and answers to key clinical practice uncertainties, including variability of response to Dobutamine in common pathophysiologies seen in newborn infants impact on longer term developmental outcomes so important to the patients, families and wider society.

Agency: European Commission | Branch: FP7 | Program: BSG-SME | Phase: SME-2011-1 | Award Amount: 1.50M | Year: 2012

ImplantDirect will create a cost-effective, faster manufacturing route for orthopaedic, maxillofacial or trauma implants, tailored to the individual needs of patients. The overall project aims are to improve the quality of the implants, reduce the recovery time, improve the quality of life for the patients and reduce the healthcare costs. This will be achieved by allowing surgeons to personalise the implants to fit the patient and the individual trauma, thus reducing the need for revisions, the length of surgery time and the recovery time of the patient. While the technology is available and can deliver the well-recognised benefits of using personalised implants, the number of clinical cases is still limited. The main reasons that the technology has not been widely applied for treatment in hospitals, are the complexity of the delivery process, the high cost of implants and the lack of human and technological resources in the area of biomodelling in hospitals. Especially, the multidisciplinary communication among radiologists, surgeons, and biomedical engineers, which is always needed during the design and manufacturing steps of a patient specific implant. In addition, the optimal solutions and funding for investment of hardware and software are not always available. The work to be undertaken in ImplantDirect will help overcome these issues by the realisation of two key innovations: 1) An innovative software solution that will allow the surgeon to directly design the best (not limited by existing manufacturing techniques) implant shape for his patients, based on CT-scan data, which will then allow implant creation using the flexible Rapid Manufacturing technique of Selective Laser Melting. 2) Develop the Selective Laser Melting process and post-processing necessary to deliver functional Ti6Al4V personalised implants within 3 days from receiving the designs from innovation 1.

Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2009-3.3-1 | Award Amount: 3.67M | Year: 2010

Truancy is a serious public health problem that affects adolescents from all countries around the world. In the United States, it has been reported that up to 35% of high school students skipped one or more days of school during a school year. However, little is known on the short- and long-term outcomes of underlying psychological and mental ill-health for those adolescents who truant. Research has indicated that truancy has severe and far reaching consequences, such as maladjustment, substance abuse, delinquency and crime. Most studies, performed in the USA, proposed mechanistic and law-enforcement interventions to prevent truancy. However this approach doesnt take in consideration the psychological distress that is associated with this phenomenon and may even have negative consequences on adolescents well-being and mental health. The main objectives of the WE-STAY (Working in Europe to Stop Truancy among Youth) project are to gather epidemiological information on truancy on European adolescents; to perform intervention school-based programmes for adolescents, aimed at reducing truancy rates and improve mental health of students; to evaluate outcomes of the interventions, in comparison with a control group, from a multidisciplinary perspective including social, psychological and economical aspects; to recommend effective, culturally adjusted models for preventing truancy and promoting mental health of adolescents in different European countries. The WE-STAY project proposes to implement and evaluate outcomes of three different kinds of intervention against truancy: a) a universal intervention based on an awareness program for students, teachers and parents; b) a screening intervention aimed at identifying students at risk and refer them to mental health services; c) a combination of the above interventions. A mechanistic intervention to stop truancy will be used as control.

Antoniu S.A.,Victor Babes University of Medicine and Pharmacy Timisoara
Current Opinion in Molecular Therapeutics | Year: 2010

In development by MedImmune LLC, under license from Genaera Corp, MEDI-528 is an injectable, humanized mAb against IL-9 for the potential treatment of asthma. In asthma, airway inflammation is usually adequately minimized with standard-of-care treatments, such as inhaled corticosteroids and leukotriene modifiers, but it is sometimes less responsive to such therapies and other anti-inflammatory approaches are required. Several T-helper cell type 2-derived cytokines, such as IL-4, -5, -9 and -13, play a major role in the development of disease pathogenic features in asthma, including airway eosinophilia, increased IgE production, mucus hypersecretion and airway hyperreactivity. As an IL-9 antagonist, MEDI-528 appears to inhibit a range of asthma pathogenic features in antigen-exposed mice. To date, clinical data are modest, although insufficient to judge the efficacy of the drug in humans, and larger and longer-term clinical trials are required. MEDI-528, along with other anticytokine therapies targeting different ILs, remains under investigation in early-phase trials for asthma. Time will tell if this form of therapy can be used as an add-on to less efficacious anti-inflammatory therapy or can replace the existing anti-inflammatory therapies in the treatment of asthma. © Thomson Reuters (Scientific) Ltd.

Antoniu S.A.,Victor Babes University of Medicine and Pharmacy Timisoara
International Journal of COPD | Year: 2011

In chronic obstructive pulmonary disease (COPD) the infammation occurring in the airways and in other lung tissues is complex and is orchestrated by various mediators including the isoenzyme 4 of the phosphodiesterases family (PDE4), which contributes to bronchoconstriction and infammation. Various PDE4 inhibitors have been evaluated as potential therapies in asthma or COPD but among these only rofumilast have been authorized in Europe to be used in patients with severe COPD as an add-on to the bronchodilator therapy. This review discusses the existing preclinical and clinical data supporting the use of rofumilast for this therapeutic indication and tackles some of the pending issues related to PDE4 in general and to rofumilast in particular. © 2011 Antoniu, publisher and licensee Dove Medical Press Ltd.

Antoniu S.A.,Victor Babes University of Medicine and Pharmacy Timisoara
Expert Opinion on Biological Therapy | Year: 2013

In asthma and chronic obstructive pulmonary disease (COPD), the inflammation in the airways cannot always be controlled with conventional therapies, such as inhaled corticosteroids. Addition of more specific anti-inflammatory therapies, such as monoclonal antibodies, against inflammation pathways might improve the disease outcome. Areas covered: This review individually discusses the major inflammation pathways and their potential blocking monoclonal antibodies in asthma and COPD. Expert opinion: The current use of omalizumab in asthma provides a good example on the potential therapeutic role of monoclonal antibodies in both asthma and COPD. There are many other monoclonal antibodies which are currently investigated as possible therapies in these diseases. The identification of the disease subsets in which such antibodies might exert the maximum benefit opens the door for personalized medicine and for targeted biological therapy in asthma and COPD. © 2013 Informa UK, Ltd.

Loading Victor Babes University of Medicine and Pharmacy Timisoara collaborators
Loading Victor Babes University of Medicine and Pharmacy Timisoara collaborators